http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H11302193-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_097405822d505467fd50f7100022cd56 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-65 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate | 1998-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68cc58f76399c957d0aae6dc18372f59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e82dfef8d5aebb3feb79e7f15b6ead1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_71568c160c02b29932d523c8185212f8 |
| publicationDate | 1999-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H11302193-A |
| titleOfInvention | Angiogenesis inhibitor |
| abstract | PROBLEM TO BE SOLVED: To provide an effective method for inhibiting angiogenesis based on a synergistic effect of a combination use of an anti-VEGF / VPF antibody and an angiogenesis inhibitor such as minocycline, particularly a method for inhibiting cancer angiogenesis. SOLUTION: An angiogenesis inhibitor comprising a VEGF / VPF antagonist and minocycline as active ingredients. VEGF The / VPF antagonist is preferably an anti-VEGF / VPF monoclonal antibody, particularly preferably an antibody that reacts with at least one of the following sequences 1-3. 1. KPSCVPLMR 2. SFLQHNKCECRP 3. KCECRPKKDRAR |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012136522-A |
| priorityDate | 1998-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.